









Markets
/
Stocks
/
nasdaq-clnn
/

Clene Inc.

CLNN

6.390USD

+0.070+1.11%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

60.46MMarket Cap

LossP/E TTM



Clene Inc.

6.390

+0.070+1.11%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

194 / 506

Overall Ranking

314 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

31.667

Target Price

+401.05%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.

Growing

The company is in a growing phase, with the latest annual income totaling USD 342.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 31.69.

Overvalued

The company’s latest PE is 0.13, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 4.24M shares, decreasing 15.37% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 188.36K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.38, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 27.00K, representing a year-over-year decrease of 70.33%, while its net profit experienced a year-over-year decrease of 9.34%.

Score

Industry at a Glance

Previous score

5.38

Change



Financials

5.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.15

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.03

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 0.13, which is -40.37% below the recent high of 0.08 and 511.18% above the recent low of -0.53.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 194/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Clene Inc. is 30.50, with a high of 48.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

31.667

Target Price

+401.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Clene Inc

CLNN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.48, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 7.45 and the support level at 4.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.48

Change

-0.31

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.090

Neutral

RSI(14)

62.062

Neutral

STOCH(KDJ)(9,3,3)

52.250

Buy

ATR(14)

0.582

Low Volatility

CCI(14)

33.406

Neutral

Williams %R

41.193

Buy

TRIX(12,20)

1.554

Sell

StochRSI(14)

92.431

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

6.292

Buy

MA10

6.314

Buy

MA20

5.979

Buy

MA50

4.692

Buy

MA100

4.075

Buy

MA200

4.163

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 47.17%, representing a quarter-over-quarter decrease of 1.63%. The largest institutional shareholder is The Vanguard, holding a total of 188.36K shares, representing 1.87% of shares outstanding, with 16.74% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Mosca (Alison)

1.31M

+231.66%

General Resonance, L.L.C.

707.99K

-0.17%

SymBiosis Capital Management, LLC

650.95K

Matlin (David J.)

451.99K

-0.00%

4life Research, L.L.C.

199.84K

-0.00%

The Vanguard Group, Inc.

Star Investors

133.33K

+2.87%

Kensington Investments, L.P.

150.33K

Scoggin Management LP

100.00K

Gay (Jonathon)

116.46K

-0.00%

Geode Capital Management, L.L.C.

68.97K

+5.93%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.14, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.